The Experts below are selected from a list of 58194 Experts worldwide ranked by ideXlab platform

Antoine Tabarin - One of the best experts on this subject based on the ideXlab platform.

  • Good Clinical Practice recommendations for the use of PET/CT in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Solène Querellou-lefranc, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards–Options–Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status—the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

  • Good Clinical Practice recommendations for the use of pet ct in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Solene Querelloulefranc, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

Pierre-yves Salaün - One of the best experts on this subject based on the ideXlab platform.

  • Good Clinical Practice recommendations for the use of PET/CT in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Solène Querellou-lefranc, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards–Options–Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status—the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

  • Good Clinical Practice recommendations for the use of pet ct in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Solene Querelloulefranc, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

David Taieb - One of the best experts on this subject based on the ideXlab platform.

  • Good Clinical Practice recommendations for the use of PET/CT in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Solène Querellou-lefranc, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards–Options–Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status—the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

  • Good Clinical Practice recommendations for the use of pet ct in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Solene Querelloulefranc, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

Myriam Wartski - One of the best experts on this subject based on the ideXlab platform.

  • Good Clinical Practice recommendations for the use of PET/CT in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Solène Querellou-lefranc, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards–Options–Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status—the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

  • Good Clinical Practice recommendations for the use of pet ct in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Solene Querelloulefranc, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

Gilles Quere - One of the best experts on this subject based on the ideXlab platform.

  • Good Clinical Practice recommendations for the use of PET/CT in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Solène Querellou-lefranc, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards–Options–Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status—the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

  • Good Clinical Practice recommendations for the use of pet ct in oncology
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Pierre-yves Salaün, Ronan Abgral, Olivier Malard, Gilles Quere, Myriam Wartski, Romain Coriat, Elif Hindie, David Taieb, Solene Querelloulefranc, Antoine Tabarin
    Abstract:

    Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven Clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French Practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing Good Clinical Practice recommendations. These Good Clinical Practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, Clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.